The industryThe industry


Québec City: A technology revolution serving the needs of health care

News - The technology revolution that has taken hold in Québec City over the past few decades has spawned a number of life sciences success stories, paving the way for the development of a wide array of technologies in numerous fields. The life sciences sector alone employs nearly 6,000 people in Québec City and generates annual sales of over $1 billion, according to figures compiled by Québec International.c

Opsens Announces a Reorganization of its Corporate Structure

News - Opsens Inc. is pleased to announce the reorganization of its corporate structure. Opsens' medical activities have taken a leading role in recent years, a result of the positive response to the performance of its products developed to measure Fractional Flow Reserve ("FFR"), their recent FDA approval which allows their marketing in the U.S., and the soon-to-come move into a state-of-the-art facility to increase manufacturing capacity and accommodate a growing number of employees. Opsens' FFR products are designed to optimize the diagnostic and guide treatment in patients with coronary heart disease.

Quebec-based H2O Innovation wins contract to help solve California’s water problems

News - Quebec City-based H2O Innovation, a company that works on custom-built, integrated water treatment solutions for municipal and energy end-users, has been awarded new contracts in the United States and Canada, which total $7 million.

Dr. Gary Kobinger, Ebola scientist who led ZMapp development, to be director of Centre for Research in Infectious Diseases in Quebec City

News - The scientist who led the work to develop the Ebola drug ZMapp is going to be leaving the National Microbiology Laboratory in Winnipeg. Dr. Gary Kobinger is the lab's chief of special pathogens, heading a team that works on some of the world's worst disease threats. Kobinger will be vacating that position next June to become the director of the Centre for Research in Infectious Diseases at Laval University in Quebec City.

Feldan : Finalist in The Redefining Early Stage Investments (RESI) Challenge

News - Life Science Nation unveiled the finalists that were hand-picked to enter the RESI Boston Innovation Challenge: an exciting group of innovative life science companies in therapeutics, diagnostics, medical devices, and healthcare information technology (HC IT). Feldan is one of the companies selected to participate in The Redefining Early Stage Investments (RESI) Challenge in Boston!

Université Laval awarded historic $98 million grant

News - Université Laval has obtained the largest research grant in its history for the massive Sentinelle Nord research program: a $98 million award from the federal government’s $350 million Canada First Research Excellence Fund.

TSO3 receives purchase orders for its STERIZONE® sterilization system - Begins shipment of STERIZONE® VP4 Sterilizers to USA

News - TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.

Opsens receives Health Canada approval to commercialize its FFR products

News - Opsens Inc. announced it has received Health Canada's approval to commercialize the OptoWire and OptoMonitor, its products developed to measure Fractional Flow Reserve ("FFR"). FFR is used to optimize the diagnosis and guide the treatment of patients with coronary heart disease.

TSO3 creates U.S. entity - Plans to open U.S. facility

News - TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings, announced the formation of a wholly owned subsidiary: TSO3 Corporation, structured under the laws of the State of Delaware, and located in the State of South Carolina, USA. The new entity is being created to meet the demands of US customers for product, service and education.

OPSENS Moves FFR Activities to Increase Manufacturing Capacity

News - Opsens Inc. announces that in light of the positive feedback on the performance of its products developed to measure Fractional Flow Reserve ("FFR"), the OptoWire and OptoMonitor ("Opsens' FFR products"), and the recent FDA approval for the commercialization of these products in the U.S., the Company is going forward with a massive expansion to increase the manufacturing capacity and accommodate its growing number of employees.


Jean-MichelGarroLife Sciences

More details


Subscribe to our newsletter for interesting news and information.

Print this page